Antibody, Clinical Trials and Recombinant Antibody

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Clinical Trials

Recombinant Antibody

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Our pipeline, for example, includes a new class of recombinant antibodies. What are key pipeline initiatives for Grifols in the coming years?

Medicine

Medicine Recombinant Antibody Protein Antibody

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

JANUARY 18, 2021

oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ BT-001 is based on the patented Invir.IO platforms, and the human GM-CSF cytokine.

Trials

Trials Antibody Engineer Clinical Trials

Clinical Research Informer

Grifols’ Innovation Strategy in the Plasma Medicine Space

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

Stay Connected